Transparency in drug regulation: mirage or oasis?
Lexchin
Joel
J
Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont. joel.lexchin@utoronto.ca
Mintzes
Barbara
B
D022126:Access to Information / Q000331:legislation & jurisprudence*; D000928:Antidepressive Agents / Q000627:therapeutic use; D015982:Bias; D002170:Canada; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D002986:Clinical Trials as Topic / Q000592:standards; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D017277:Drug Approval / Q000458:organization & administration*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D011643:Publishing / Q000592:standards; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects
D000928:Antidepressive Agents; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib